Chondroxide®
International non-proprietary name
Dosage form
Tablets 250 mg
Compound
One tablet contains
active substance- chondroitin sulfate sodium 250 mg,
Excipients: calcium stearate, crospovidone, povidone K-30, microcrystalline cellulose, magnesium hydroxycarbonate pentahydrate.
Description
Tablets are round-shaped, with a flat surface, from white to white with a yellowish or creamy tint, with a notch and a chamfer, inclusions are allowed
Pharmacotherapeutic group
Anti-inflammatory and antirheumatic drugs. Non-steroidal anti-inflammatory drugs. Other non-steroidal anti-inflammatory drugs. Chondroitin sulfate
ATX code M01AX25
Pharmacological properties
Pharmacokinetics
Suction
With a single oral dose of the average therapeutic dose, the maximum concentration in the blood plasma is reached after 3-4 hours, in the synovial fluid - after 4-5 hours. The bioavailability of the drug is 13%.
Distribution
Accumulates mainly in cartilage tissue(the maximum concentration in the articular cartilage is reached after 48 hours); the synovium is not an obstacle to its penetration into the joint cavity.
breeding
Excreted by the kidneys within 24 hours.
Pharmacodynamics
Chondroxide® has a chondrostimulating, regenerating and anti-inflammatory effect, participates in the construction of the basic substance of cartilage and bone tissue; affects metabolic processes in hyaline and fibrous cartilage. It inhibits the processes of degeneration (destruction) of cartilaginous tissue and stimulates regenerative processes in articular cartilage.
Chondroxide® stimulates the biosynthesis of proteoglycans, promotes the regeneration of the articular bag and cartilaginous surfaces of the joints, and has an anti-inflammatory effect. It slows down the resorption of bone tissue and reduces the loss of calcium, accelerates the processes of bone tissue restoration.
Chondroxide® slows down the progression of osteoarthritis and osteochondrosis. When using the drug Chondroxide®, pain decreases and the mobility of the affected joints improves, while the therapeutic effect persists for a long time after the end of the course of therapy.
Having a structural similarity with heparin, it can potentially prevent the formation of fibrin clots in the synovial and subchondral microvasculature.
Indications for use
degenerative-dystrophic diseases of the joints and spine (osteoarthritis, including osteoarthritis of the temporomandibular joint, spondylarthrosis, osteochondrosis, osteoporosis, cheiroarthropathies)
Dosage and administration
Inside, 0.5 g (2 tablets) 2 times a day.
Tablets are taken with a small amount of water.
The recommended duration of the initial course is 6 months. It should be borne in mind that the therapeutic effect of the drug persists for 3-5 months after its withdrawal, depending on the location and stage of the disease. If necessary, it is possible to conduct repeated courses of treatment, the duration of which is determined individually.
Side effects
Rare (>0.01% to< 0,1%)
allergic reactions
nausea, vomiting, constipation, epigastric pain, flatulence, diarrhea
Contraindications
hypersensitivity to drug components
children and adolescents up to 18 years of age
pregnancy
lactation period
tendency to bleeding, thrombophlebitis
severe renal dysfunction
Drug Interactions
It is possible to enhance the action of indirect anticoagulants, antiplatelet agents, fibrinolytics.
special instructions
When the drug is used together with indirect anticoagulants, antiplatelet agents, fibrinolytics, more frequent monitoring of blood coagulation parameters is required. Not to be used for bleeding or bleeding tendency.
Features of the effect of the drug on the ability to drive a car or potentially dangerous mechanisms
Does not affect ability to drive vehicle or potentially dangerous machinery.
Overdose
In accordance with the instructions for use, Chondroxide tablets are taken to stimulate the restoration of cartilage, slow down destructive processes in the musculoskeletal system, eliminate pain syndrome and joint stiffness.
Aching pain, difficulty in flexion-extension of the joint, characteristic, violation of natural mobility are all signs of degenerative changes in the joints that cannot be ignored. These processes can and should be abandoned! For people with such problems, specialists develop individual complex treatment schemes, consisting of drug therapy, medical gymnastics. One of the effective ones included in the therapeutic course is Chondroxide - medicine pertaining to pharmacological group correctors of cartilage and bone tissue metabolism.
For oral administration Chondroxide is available in the form of tablets packed in polymer blisters of 10 pieces. Tablets are white with small patches, may have a cream or yellowish tint.
Each tablet contains 250 mg active ingredient- chondroitin sulfate and auxiliary components.
The drug goes on sale in pharmacy chains in cardboard boxes containing 3, 5, 6, 9 or 10 blister packs, including instructions for using the drug.
Chondroxide tablets are produced in Russia by the Nizhpharm pharmaceutical company in Nizhny Novgorod (OJSC).
pharmachologic effect
The active component of the drug Chondroxide chondroitin sulfate is found in human cartilage tissue. Substance natural origin, obtained from the cartilage extract of cattle and pigs, helps the joints maintain elasticity and flexibility, slows down the process of bone resorption, and also participates in the synthesis of synovial fluid.
Involved in metabolic processes, chondroitin sulfate has the following types of effects:
- improves phosphorus-calcium metabolism;
- stimulates the synthesis of glucosamines;
- inhibits the production of enzymes that destroy connective tissue.
The maximum level of the content of the active substance in plasma after oral administration is achieved within 3-4 hours, in the joint fluid after 4-5 hours, in the cartilage tissue after 48 hours. Bioavailability within 12-13%. The drug is excreted through the kidneys within a day after ingestion.
The complex effect of the drug on bone and cartilage tissue leads to a decrease in the intensity of the pain syndrome, an improvement in the motor activity of the joints.
Patients who have completed a full course of treatment with Chondroxide note a significant expansion of the range of motion as an important effect of therapy, which has a positive effect on the quality of life.
Such physical activity skills as deep inclinations, squats, retraction of limbs forward, backward, to the sides are returning. The gait becomes more free, relaxed. It is the stiffness of the joints, as well as the deformation of the vertebrae, that give the gait a specific character - this is falling sideways, rocking the body, excessive caution when descending stairs, the inability to overcome a low rise.
Taking chondroprotectors allows you to restore motor activity, but the degree of rehabilitation depends on the stage at which the patient went to the doctor, how accurately the diagnosis was made and the treatment regimen developed, and how punctually the patient followed the doctor's recommendations.
Indications for use
The grounds for the appointment of Chondroxide are the following diseases and pathologies:
Chondroxide is a long-term drug prescribed for the treatment and prevention of the development of degenerative-dystrophic changes in the joints.
Dosage
Chondroxide is taken for therapeutic and prophylactic purposes at 500 mg per day (2 tablets of 250 mg). The daily amount of the drug is divided into 2 times. Tablets are washed down with a small amount of water.
The duration of treatment is 5-6 months.
At the discretion of the physician, the dose may be increased to 750 mg per day.
The effect of the drug persists for 3-6 months after the completion of the therapeutic program.
Contraindications
Absolute contraindications to the use of the drug are diseases of the hematopoietic organs, pregnancy and lactation.
Chondroxide is prescribed with caution with a tendency to allergic reactions, in the post-infarction and post-stroke periods, with severe renal and hepatic insufficiency.
During pregnancy and breastfeeding the drug is not prescribed as a precaution, since there is no strong evidence of harm to the body of the mother and child.
Side effects
The drug is well tolerated by patients, in most cases. Severe side effects were rarely observed in medical practice.
The greatest number of complications is recorded from the side gastrointestinal tract. This is diarrhea, nausea, vomiting, flatulence.
In the first days of treatment, rashes on the skin (rash, red spots) are possible. After 2 weeks of use, unwanted effects usually disappear completely.
Overdose
Signs of an overdose are pronounced side effects.
If the patient develops vomiting, diarrhea, general weakness occurs, the drug should be discontinued immediately.
Symptoms of an overdose may occur when taking Chondroxide in an amount of more than three grams per day. Treatment is aimed at stopping unwanted symptoms. Typically specialized health care the patient is not required. Pharmacological agent does not contain toxic components.
Interaction with drugs
When taking Chondroxide in tablets, there may be an increase in the action of indirect anticoagulants and fibrinolytics. If the patient takes the above pharmacological agents, it is necessary to monitor blood clotting parameters.
Chondroitin can change the concentration of tetracycline antibiotics in the blood serum. These features of the effect of the drug on the body in various schemes of interaction of pharmacological agents should be taken into account when drawing up the program of the treatment course.
Storage conditions
The drug is stored at room temperature, not exceeding 25 degrees, in a dark place.
Price
The price of the drug depends on the number of tablets in the sales package.
Chondroxide belongs to relatively inexpensive drugs in the category of drugs used in complex treatment degenerative pathologies of the musculoskeletal system.
The cost of a package of Chondroxide of 60 tablets, which is enough to take for 1 month, varies from 590 to 650 rubles.
Analogues
Among the analogues of the pharmacological agent Chondroxide, the following preparations can be mentioned, which have a tablet or capsule form of release for oral administration:
Registration number: LS-002295-090714
Trade name of the drug: Chondroxide®
International generic name:
chondroitin sulfate
Dosage form:
pills
Compound
1 tablet contains:
active substance: chondroitin sulfate sodium - 250.0 mg;
Excipients: calcium stearate - 4.8 mg, crospovidone - 12.39 mg, povidone-K30 - 9.312 mg, microcrystalline cellulose - 96.0 mg, magnesium hydroxycarbonate pentahydrate - 107.498 mg.
Description:
tablets from white to white with a yellowish or creamy tint, blotches are allowed, with a risk and a chamfer.
Pharmacotherapeutic group: tissue repair stimulant of natural origin.
ATX code
Pharmacological properties
It has a chondrostimulating, regenerating, anti-inflammatory effect. Chondroxide is involved in the construction of the basic substance of cartilage and bone tissue; affects metabolic processes in hyaline and fibrous cartilage, inhibits enzymes that cause damage to cartilage. The drug inhibits the destruction of cartilage tissue and stimulates the regenerative processes in the articular cartilage.
Chondroxide® stimulates the biosynthesis of proteoglycans, promotes the regeneration of the articular bag and cartilaginous surfaces of the joints, and has an anti-inflammatory effect. It slows down the resorption of bone tissue and reduces the loss of calcium, accelerates the processes of bone tissue restoration.
Chondroxide® slows down the progression of osteoarthritis and osteochondrosis. When using the drug Chondroxide®, pain decreases and the mobility of the affected joints improves, while the therapeutic effect persists for a long time after the end of the course of therapy.
Having a structural similarity with heparin, it can potentially prevent the formation of fibrin clots in the synovial and subchondral microvasculature.
Suction
With a single oral dose of the average therapeutic dose, the maximum plasma concentration is reached after 3-4 hours, in the synovial fluid - after 4-5 hours. The bioavailability of the drug is 13%.
Distribution
Accumulates mainly in cartilage (maximum concentration in articular cartilage is reached after 48 hours); the synovium is not an obstacle to its penetration into the joint cavity.
breeding
Excreted by the kidneys within 24 hours.
Indications for use
Degenerative-dystrophic diseases of the joints and spine: treatment and prevention of osteoarthritis, osteochondrosis of the spine.
Contraindications
Hypersensitivity to the components of the drug, children's age (efficacy and safety of use in children have not been established), pregnancy, breastfeeding period.
Carefully
Bleeding, tendency to bleed.
Dosage and administration
Inside, 0.5 g (2 tablets) 2 times a day.
Tablets are taken with a small amount of water.
The recommended duration of the initial course of treatment is 6 months.
The therapeutic effect of the drug persists for 3-5 months after its withdrawal, depending on the location and stage of the disease. If necessary, it is possible to conduct repeated courses of treatment, the duration of which is determined individually.
Side effect
Frequency estimate: rarely - from >= 0.01% to rarely - nausea, vomiting, diarrhea,
rarely - allergic reactions.
Overdose
Symptoms: rarely - nausea, vomiting, diarrhea, with prolonged use in excessively high doses (more than 3 g / day), hemorrhagic rashes are possible.
Treatment: conducting symptomatic therapy.
Interaction with other drugs
It is possible to enhance the action of indirect anticoagulants, antiplatelet agents, fibrinolytics.
special instructions
When the drug is used together with indirect anticoagulants, antiplatelet agents, fibrinolytics, more frequent monitoring of blood coagulation parameters is required.
Influence on the ability to drive a car and mechanisms
Does not affect the ability to drive a car and other mechanisms.
Release form
Tablets 250 mg. 10 tablets in a blister pack. 3, 5, 6, 9 or 10 blister packs with instructions for use medical use the drug is placed in a cardboard box.
Storage conditions
In a dry place protected from light at a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Chondroxide refers to drugs that regulate the metabolism in cartilage tissue.
Release form and composition of Chondroxide
Chondroxide is produced in the form of three dosage forms:
- tablets containing the active substance - chondroitin sulfate in the amount of 250 mg / pc. There are packages of 30 tablets and 60;
- gel for external use. Packing - tube, in which 30 g of 5% gel. The amount of chondroitin sulfate - 50 mg / g;
- ointment 5% also in tubes with a capacity of 30 g, chondroitin sulfate - 50 mg / g.
Among the additional components that make up Chondroxide are the following: anhydrous lanolin, purified water, dimethyl sulfoxide, petroleum jelly.
Chondroxide analogues are drugs such as: Artrin, Structum, Mucosat, Chondrogard, Chondrolon, Chondroitin.
Pharmacological action of Chondroxide
Chondroxide has chondrostimulating, regenerating and anti-inflammatory effects.
According to the instructions, Chondroxide takes part in the construction of the basic substance of bone and cartilage tissue. Influences metabolic processes in fibrous and hyaline cartilage. It helps to reduce the rate of degenerative processes in the connective and cartilage tissue, slows down or stops the activity of enzymes that cause damage to cartilage tissue.
Through action active substance as part of Chondroxide, the biosynthesis of proteoglycans occurs faster, the regeneration of the cartilaginous surfaces of the joints is restored, and the production of intra-articular fluid increases. In addition, bone resorption slows down, calcium loss decreases, and bone tissue recovery accelerates.
According to reviews of Chondroxide, its use helps to slow down the development of osteochondrosis and osteoarthritis, under the influence of the drug, pain decreases and the mobility of the affected joints increases, which greatly facilitates the patient's life. The therapeutic effect of the drug is maintained for a long time after the end of treatment.
Indications for the use of Chondroxide
The drug in the form of an ointment and gel is prescribed to prevent osteochondrosis of the spine and osteoarthritis of peripheral joints. Chondroxide according to the instructions is also used for degenerative-dystrophic diseases of the spine and joints.
Dosage regimen and method of application Chondroxide
According to the instructions, Chondroxide gel and ointment are intended for external use. A thin layer of the drug is applied to the focus of inflammation, rubbed for some time until the drug is completely absorbed. The procedure is carried out two or three times a day. Treatment is usually continued from 2 weeks to 3 months.
Chondroxide tablets are taken orally. Chondroxide analogues, like the drug itself, are taken twice a day, 500 mg each. Duration of treatment - more than six months. Moreover, the dosage and duration of the course are the same for both therapeutic and prophylactic purposes.
If necessary, it is possible repeated course therapy, the duration of which is determined by the attending physician.
Contraindications
The drug Chondroxide in the form of an ointment and gel is not recommended for use in case of hypersensitivity or intolerance to chondroitin. The drug in the form of tablets is also forbidden to use during pregnancy and lactation.
Side effects of Chondroxide
According to reviews, the gel and ointment of Chondroxide do not cause side effects if they are used in the dosages recommended by the instructions. But still, sometimes patients develop allergic skin rashes. In this case, the use of the drug is stopped.
Taking Chondroxide tablets can cause side effects such as nausea, diarrhea, and in very high doses (more than three grams per day) - hemorrhagic rashes. To reduce or completely remove such conditions, symptomatic therapy is carried out.
special instructions
The drug in the form of tablets is prescribed with extreme caution if the patient has bleeding or has a tendency to them.
The use of Chondroxide in childhood allowed only after consultation with the attending physician.
With the simultaneous use of the drug with fibrinolytics, antiplatelet agents and indirect anticoagulants, frequent monitoring of indicators characterizing blood clotting is necessary.
Terms and conditions of storage
The drug belongs to the group of prescription drugs. Chondroxide analogs, like the drug itself, are stored in a dry, dark place, protected from children. The optimum storage temperature is no more than 25 degrees Celsius. The shelf life during which the drug retains its properties is two years.
Chondroxide (INN chondroitin sulfate) - a stimulant for the restoration of cartilage tissue of the joint from the Russian pharmaceutical company LLC "Nizhpharm", one of the three leaders among domestic manufacturers medicines. It is produced in the form of an injection solution, tablets, as well as external forms - ointments and creams, and in the latter case, the manufacturer managed to achieve an unprecedented high content active ingredient. The systemic use of NSAIDs in osteochondrosis, osteoarthritis and other degenerative-dystrophic diseases is fraught with serious adverse reactions, which increases the importance of effective local therapy: it is convenient, safe, does not entail the risk of unwanted pharmacological interactions and provides a therapeutic effect directly on the focus of the pathological process. The oral form of chondroitin sulfate has a low (13%) bioavailability, due to the impressive molecular weight of the active substance. In this regard, other ways of delivering the active component to the affected tissues, in particular, the local dosage form, are becoming increasingly important. The bioavailability of Chondroxide in the form of an ointment or cream is about 30%, which should be considered a very good indicator. The ointment contains dimethyl sulfoxide as an auxiliary component, which ensures effective penetration of chondroitin sulfate through skin and mucous membranes to the affected joints and spine.
It is important that Chondroxide has a pronounced ability to slow down the destructive processes in cartilage tissue and stimulate its regeneration. As a result, this leads to the removal of pain and an increase in joint mobility. The drug has an extremely favorable safety profile and, when used at doses recommended by the manufacturer, has practically no side effects. side effects. OTC status of the drug allows the possibility of its use in the framework of responsible and controlled self-medication. Chondroxide not only significantly reduces the severity of pain, but also has a direct effect on the cause of its occurrence - on the main pathogenetic link in the formation of pain syndrome, providing effective regeneration of the cartilage tissue of the damaged joint. An important caveat: this process requires a certain amount of time: the duration of the use of the drug must be at least one month. Domestic doctors have accumulated considerable experience in the clinical use of Chondroxide. One of the studies was carried out in Tatarstan within the walls of the Kazan State Medical Academy. Scientists compared the effectiveness of Chondroxide and Ibuprofen in the treatment of lumboischialgia (lumbar pain syndrome). The results of the clinical trial proved the high analgesic efficacy of Chondroxide: after 14 days of treatment, the intensity of the pain syndrome in patients decreased by half.
Pharmacology
The agent that affects the phosphorus-calcium metabolism in cartilage tissue is a high molecular weight mucopolysaccharide. It slows down the resorption of bone tissue and reduces the loss of calcium, accelerates the processes of restoration of bone tissue, and inhibits the process of cartilage tissue degeneration. It prevents the contraction of the connective tissue and plays the role of a kind of lubrication of the articular surfaces. When applied externally, it slows down the progression of osteoarthritis. Normalizes metabolism in hyaline tissue. Stimulates the regeneration of articular cartilage.
Pharmacokinetics
With a single oral administration of the average therapeutic dose, Cmax in plasma is achieved after 3-4 hours, in synovial fluid - after 4-5 hours. Bioavailability is 13%. Excreted by the kidneys within 24 hours.Release form
The solution for intramuscular injection is clear, colorless or with a slightly yellowish tint, with the smell of benzyl alcohol.
Excipients: benzyl alcohol - 9 mg, water for injection - up to 1 ml.
1 ml - glass ampoules (5) - blister packs (1) - cardboard packs.
1 ml - glass ampoules (5) - blister packs (2) - cardboard packs.
2 ml - glass ampoules (5) - blister packs (1) - cardboard packs.
2 ml - glass ampoules (5) - blister packs (2) - cardboard packs.
Dosage
Inside adults - 1.5-1 g 2 times / day.
Outwardly - 2 times / day for 2-3 weeks.
Side effects
Rarely: allergic reactions.
Indications
Osteoporosis, periodontal disease, fractures (to accelerate the formation of callus), degenerative-dystrophic diseases of the joints and spine.
Contraindications
Hypersensitivity to chondroitin sulfate, tendency to bleeding, thrombophlebitis, pregnancy, lactation (breastfeeding).
Application features
Use during pregnancy and lactation
Chondroitin sulfate is contraindicated for use during pregnancy and lactation (breastfeeding).Use in elderly patients
special instructions
At various forms periodontopathy, the course of treatment should be continued for at least 3 months.
There are clinical data on the use of chondroitin sulfate in elderly patients with atherosclerosis, while there was a slight decrease in the concentration of cholesterol and triglycerides in the blood plasma.